China Fusion Biopsy Market Size & Outlook, 2023-2030
China fusion biopsy market, 2018-2030 (US$M)
Related Markets
China fusion biopsy market highlights
- The China fusion biopsy market generated a revenue of USD 28.2 million in 2023 and is expected to reach USD 56.3 million by 2030.
- The China market is expected to grow at a CAGR of 10.4% from 2024 to 2030.
- In terms of segment, transrectal was the largest revenue generating biopsy route in 2023.
- Transperineal is the most lucrative biopsy route segment registering the fastest growth during the forecast period.
Fusion biopsy market data book summary
| Market revenue in 2023 | USD 28.2 million |
| Market revenue in 2030 | USD 56.3 million |
| Growth rate | 10.4% (CAGR from 2023 to 2030) |
| Largest segment | Transrectal |
| Fastest growing segment | Transperineal |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Transrectal, Transperineal |
| Key market players worldwide | Koninklijke Philips NV, Hitachi Ltd, Esaote, Eigen, MedCom, Koelis, Focal Healthcare, UC Care |
Other key industry trends
- In terms of revenue, China accounted for 4.5% of the global fusion biopsy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan fusion biopsy market is projected to lead the regional market in terms of revenue in 2030.
- Japan is the fastest growing regional market in Asia Pacific and is projected to reach USD 67.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Fusion Biopsy Market Scope
Fusion Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China fusion biopsy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to fusion biopsy market will help companies and investors design strategic landscapes.
Transrectal was the largest segment with a revenue share of 85.11% in 2023. Horizon Databook has segmented the China fusion biopsy market based on transrectal, transperineal covering the revenue growth of each sub-segment from 2018 to 2030.
China’s fusion biopsy market was valued at USD 20.0 million in 2020 and is expected to reach a value of USD 47.7 million in 2028. China has been facing the issue of a rising death rate owing to increasing incidence of cancers. Lung, breast, stomach, colorectal, and prostate cancers have the highest incidences in China.
China faces a major issue of increasing prostate cancer cases, which is the tenth most common cause of death and the seventh most diagnosed type of cancer. In China, prostate cancer is typically diagnosed at the metastatic stage, resulting in a higher mortality rate. This is primarily due to the lack of mandatory or regular screening.
Moreover, the increasing aging population is one of the major factors expected to drive the market. According to the World Population Ageing 2019 by the UN, China’s total population of individuals aged above 65 years was 164,487.
Reasons to subscribe to China fusion biopsy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China fusion biopsy market databook
-
Our clientele includes a mix of fusion biopsy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China fusion biopsy market , including forecasts for subscribers. This country databook contains high-level insights into China fusion biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China fusion biopsy market size, by biopsy route, 2018-2030 (US$M)
China Fusion Biopsy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
